Literature DB >> 19338147

[Influence of xlaoliu baofei pill combined with chemotherapy on quality of life of patients with advanced non-small cell lung cancer].

Hong-xin Sun1, Jin Qin, Yi-qiang Zhou.   

Abstract

OBJECTIVE: To objectively assess the influence of Xiaoliu Baofei Pill (XBP) combined with chemotherapy on quality of life (QOL) of patients with stage III-IV non-small cell lung cancer (NSCLC).
METHODS: Forty NSCLC patients were equally randomized into 2 groups, the treated group treated with XBP plus chemotherapy, and the control group treated with chemotherapy alone. Patients' QOL was assessed by Functional Assessment of Cancer Therapy (FACT-L) before and after treatment.
RESULTS: The scores of the physical condition in the treated group was relatively stable while it lowered significantly as time went by in the control group, significant difference was shown as compared with before treatment and with that in the treated group at the same time points (P < 0.05); scores of the mood condition, the function conditions and additional concerned condition were improved gradually from the 3rd collection in the treated group, but decreased in the control group, although some improvement of mood and function conditions had revealed temporarily in the early stage of treatment. Comparison between groups showed significant difference (P < 0.05). Besides, no significant change was found in domains of patient-doctor relation and society/family condition in both groups.
CONCLUSION: XBP combined with chemotherapy can obviously improve the QOL of advanced NSCLC patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19338147

Source DB:  PubMed          Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi        ISSN: 1003-5370


  1 in total

1.  Effect of Feitai Capsule () on quality of life and progression-free survival of patients with unresectable non-small cell lung cancer.

Authors:  Zong-Yang Yu; Zhi-Zhen Liu; Xue-Nong Ouyang; Jian Du; Xi-Hu Dai; Xi Chen; Zhong-Quan Zhao; Wen-Wu Wang; Jie Li
Journal:  Chin J Integr Med       Date:  2012-02-05       Impact factor: 1.978

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.